Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 28, 2025
Subject: Regulatory acceptance of new drug applications (NDAs) for depemokimab in China and Japan for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).
Key Financial Metrics
This filing is a regulatory update regarding clinical development and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Developments
- Regulatory Milestones: The China National Medical Products Administration (NMPA) has accepted NDAs for depemokimab. Applications have been submitted to the Japanese Ministry of Health, Labour and Welfare (MHLW).
- Indications:
- China: Add-on maintenance treatment for asthma (adults/adolescents 12+) with type 2 inflammation and CRSwNP.
- Japan: Treatment of severe/refractory bronchial asthma and CRSwNP inadequately controlled with standard treatment.
- Clinical Data Basis: Submissions rely on positive Phase III data from the SWIFT-1, SWIFT-2 (asthma), and ANCHOR-1, ANCHOR-2 (CRSwNP) trials.
- Dosing Advantage: Depemokimab is the first ultra-long-acting biologic evaluated in Phase III for these conditions, supporting a 6-month (26-week) dosing regimen (two injections per year).
Outlook, Management Commentary, and Risks
Management Commentary: Kaivan Khavandi, SVP Global Head of Respiratory/Immunology R&D, stated that simultaneous submissions highlight confidence in depemokimab's potential to reduce disease burden through sustained inhibition of IL-5 with improved patient adherence due to the extended dosing interval.
Pipeline Context: Depemokimab is currently not approved in any country. Additional Phase III trials are ongoing for eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES).
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2023 Form 20-F and Q3 2024 results, including regulatory approval uncertainties.
Investor Verification Checklist
- Confirm the specific regulatory review timelines and expected decision dates from the NMPA (China) and MHLW (Japan).
- Verify the commercial launch strategy and pricing assumptions for depemokimab in China and Japan upon potential approval.
- Review the full clinical data from SWIFT and ANCHOR trials to assess long-term safety profiles and comparative efficacy against existing biologics.
- Monitor the status of the NIMBLE trial, which assesses switching patients from mepolizumab or benralizumab to depemokimab.
- Check for any subsequent updates regarding the OCEAN (EGPA) and DESTINY (HES) trials.